Nurix Therapeutics, Inc. Collaboration Agreements
10 Contracts & Agreements
- Sixth Amendment to Collaboration and License Agreement, dated March 6, 2024, by and between the Registrant and Genzyme Corporation (Filed With SEC on April 10, 2024)
- Fifth Amendment to Collaboration and License Agreement, dated November 3, 2023, by and between the Registrant and Genzyme Corporation (Filed With SEC on February 15, 2024)
- Fourth Amendment to Collaboration and License Agreement, dated August 11, 2022, by and between the Registrant and Genzyme Corporation (Filed With SEC on October 6, 2022)
- Third Amendment to Collaboration and License Agreement, dated July 7, 2022, by and between the Registrant and Genzyme Corporation (Filed With SEC on October 6, 2022)
- Second Amendment to Collaboration and License Agreement, dated December 16, 2021, by and between the Registrant and Genzyme Corporation (Filed With SEC on October 6, 2022)
- Second Amendment to Collaboration, Option and License Agreement, dated September 9, 2022, by and between the Registrant and Gilead Sciences, Inc (Filed With SEC on October 6, 2022)
- First Amendment to Collaboration, Option and License Agreement, dated August 13, 2019, by and between the Registrant and Gilead Sciences, Inc (Filed With SEC on October 6, 2022)
- First Amendment to Collaboration and License Agreement, dated January 6, 2021, by and between the Registrant and Genzyme Corporation (Filed With SEC on February 16, 2021)
- Collaboration and License Agreement, dated December 19, 2019, by and between the Registrant and Genzyme Corporation (Filed With SEC on July 2, 2020)
- Collaboration, Option and License Agreement, dated June 10, 2019, by and between the Registrant and Gilead Sciences, Inc., as amended (Filed With SEC on July 2, 2020)
